^
    4d
    Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, Chulalongkorn University | Trial primary completion date: Dec 2026 --> Dec 2027 | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule) • IL7R (Interleukin 7 Receptor)
    10d
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    1m
    Study of Intracerebroventricular MT027 in Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, T-MAXIMUM Pharmaceutical Inc
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
    |
    MT027
    1m
    A Dose-escalation and Dose-expansion Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile, and Efficacy of MT027 Cell Injection in Patients with Lung Cancer Complicated by Brain and/or Leptomeningeal Metastases (ChiCTR2600116919)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    MT027
    1m
    A Phase I Dose-Escalation and Dose-Expansion Clinical Study Evaluating the Tolerability, Safety, Pharmacokinetics , and Efficacy of MT027 Cell Injection in Patients with Triple-Negative Breast Cancer and Brain Metastases (ChiCTR2600116792)
    P1, N=22, Not yet recruiting, Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule)
    |
    ER negative
    |
    MT027
    4ms
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T
    4ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    4ms
    Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=85, Recruiting, Tcelltech Inc.
    New P1 trial
    4ms
    A single-arm, dose-escalation, exploratory clinical study to evaluate the tolerability, safety, pharmacokinetic profile and preliminary efficacy of MT027 cell injection in patients with malignant solid tumours metastatic to the brain, brain (spinal) membrane and spinal cord (ChiCTR2500107346)
    P=N/A, N=9, Recruiting, FuJIan SanBo FuNeng Brain Hospital; FuJIan SanBo FuNeng Brain Hospital
    New trial
    |
    CD276 (CD276 Molecule)
    |
    MT027
    4ms
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T
    4ms
    GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts. (PubMed, Mol Ther Oncol)
    GPC2-CARs lead to significant in vivo tumor regression in orthotopic tumor models via intravenous or intraventricular administration route and had equivalent activity to the B7-H3-CAR against D283 and enhanced activity than GD2-CAR in both models in vivo. T cell kinetic studies revealed that GPC2-CAR T cells home to the area of the primary tumor, expand, and upregulate genes critical for cytotoxicity and T cell homing. These results provide a preclinical rationale for including children with GPC2+ MB in our upcoming clinical GPC2-CAR T cell trial.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    5ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial • First-in-human